图片来源：http://www.zymeworks.com/our-platforms/azymetric%E2%84%A2-platform
在研产品
截止到2016年5月的114款双特异性抗体药物，按研发阶段统计如下(9款药物研发阶段未知，未列出)
数据图片来源：药渡
参考资料：
[1]Perennial dealmaker Zymeworks licenses new drug discovery platform
[2]Gilead bags Genmab tech to develop bispecific antibodyagainst HIV
[3]114个在研双特异性抗体药物统计
In ChemPartner Antibody Discovery team, over 160 scientists, 30 of which are PhD/MDs, aim to cover all the areas where our clients have needs. Our scientists are capable of discovering novel high-affinity monoclonal antibodies by hybridoma technology and single chain phage display technology. They can also develop humanized mouse monoclonal antibodies, affinity matured monoclonal antibodies and antibody-drug conjugates.
ShangPharma is comprised of a family of companies including China Gateway Biologics, China Gateway Pharmaceutical Development, ChemPartner, ShangPharma Technology and ShangPharma Investment. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry. ShangPharma aims, through all its divisions, to create an ecosystem that allows close interaction between major hospitals and academic centers, by matching them with pharmas, biotech, and research institutes to enable the success of all.
